Search Results

There are 1670 results for: content related to: Effectiveness and safety of omalizumab in a patient with chronic urticaria and hepatitis C

  1. You have free access to this content
    Omalizumab for asthma in adults and children

    Intervention Review

    The Cochrane Library

    Rebecca Normansell, Samantha Walker, Stephen J Milan, E. Haydn Walters and Parameswaran Nair

    Published Online : 13 JAN 2014, DOI: 10.1002/14651858.CD003559.pub4

  2. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy

    Clinical & Experimental Allergy

    Volume 35, Issue 4, April 2005, Pages: 408–416, S. T. Holgate, R. Djukanović, T. Casale and J. Bousquet

    Version of Record online : 11 APR 2005, DOI: 10.1111/j.1365-2222.2005.02191.x

  3. You have free access to this content
    An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma


    Volume 63, Issue 6, June 2008, Pages: 670–684, S. D. Sullivan and F. Turk

    Version of Record online : 25 APR 2008, DOI: 10.1111/j.1398-9995.2008.01723.x

  4. You have free access to this content
    EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders


    Volume 70, Issue 7, July 2015, Pages: 727–754, O. Boyman, C. Kaegi, M. Akdis, S. Bavbek, A. Bossios, A. Chatzipetrou, T. Eiwegger, D. Firinu, T. Harr, E. Knol, A. Matucci, O. Palomares, C. Schmidt-Weber, H.-U. Simon, U. C. Steiner, A. Vultaggio, C. A. Akdis and F. Spertini

    Version of Record online : 24 APR 2015, DOI: 10.1111/all.12616

  5. Safety and tolerability of omalizumab

    Clinical & Experimental Allergy

    Volume 39, Issue 6, June 2009, Pages: 788–797, J. Corren, T. B. Casale, B. Lanier, R. Buhl, S. Holgate and P. Jimenez

    Version of Record online : 17 MAR 2009, DOI: 10.1111/j.1365-2222.2009.03214.x

  6. You have free access to this content
    Effects of omalizumab on markers of inflammation in patients with allergic asthma


    Volume 64, Issue 12, December 2009, Pages: 1728–1736, S. Holgate, N. Smith, M. Massanari and P. Jimenez

    Version of Record online : 15 OCT 2009, DOI: 10.1111/j.1398-9995.2009.02201.x

  7. Omalizumab for the Treatment of Chronic Idiopathic Urticaria: Systematic Review of the Literature

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 37, Issue 4, April 2017, Pages: 464–480, Alessandro Tonacci, Lucia Billeci, Giovanni Pioggia, Michele Navarra and Sebastiano Gangemi

    Version of Record online : 23 MAR 2017, DOI: 10.1002/phar.1915

  8. You have free access to this content
    Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria

    Journal of the European Academy of Dermatology and Venereology

    Volume 30, Issue S5, July 2016, Pages: 25–32, A. M. Giménez-Arnau, E. Toubi, A. M. Marsland and M. Maurer

    Version of Record online : 10 JUN 2016, DOI: 10.1111/jdv.13697

  9. You have free access to this content
    Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria


    Volume 72, Issue 4, April 2017, Pages: 519–533, A. P. Kaplan, A. M. Giménez-Arnau and S. S. Saini

    Version of Record online : 4 JAN 2017, DOI: 10.1111/all.13083

  10. Case series of omalizumab for allergic bronchopulmonary aspergillosis in cystic fibrosis patients

    Pediatric Pulmonology

    Volume 52, Issue 2, February 2017, Pages: 190–197, Raphaële Nové-Josserand, Soazic Grard, Lila Auzou, Philippe Reix, Marlène Murris-Espin, François Brémont, Benyebka Mammar, Laurent Mely, Dominique Hubert, Isabelle Durieu and Pierre-Régis Burgel

    Version of Record online : 7 OCT 2016, DOI: 10.1002/ppul.23612

  11. You have free access to this content
    Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE

    British Journal of Clinical Pharmacology

    Volume 72, Issue 2, August 2011, Pages: 306–320, Philip J. Lowe and Didier Renard

    Version of Record online : 11 JUL 2011, DOI: 10.1111/j.1365-2125.2011.03962.x

  12. The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective


    Volume 65, Issue 9, September 2010, Pages: 1141–1148, J. D. Campbell, D. E. Spackman and S. D. Sullivan

    Version of Record online : 10 FEB 2010, DOI: 10.1111/j.1398-9995.2010.02336.x

  13. You have free access to this content
    A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab

    British Journal of Clinical Pharmacology

    Volume 63, Issue 5, May 2007, Pages: 548–561, Naoto Hayashi, Yuko Tsukamoto, William M. Sallas and Philip J. Lowe

    Version of Record online : 10 NOV 2006, DOI: 10.1111/j.1365-2125.2006.02803.x

  14. You have free access to this content
    Anti-IgE Monoclonal Antibody (Omalizumab) in Refractory and Relapsing Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss): Data on Seventeen Patients

    Arthritis & Rheumatology

    Volume 68, Issue 9, September 2016, Pages: 2274–2282, Marie Jachiet, Maxime Samson, Vincent Cottin, Jean-Emmanuel Kahn, Guillaume Le Guenno, Philippe Bonniaud, Hervé Devilliers, Laurence Bouillet, Anne Gondouin, Fatma Makhlouf, Nadine Meaux-Ruault, Helder Gil, Boris Bienvenu, André Coste, Matthieu Groh, Violaine Giraud, Stéphane Dominique, Bertrand Godeau, Xavier Puéchal, Chahera Khouatra, Marc Ruivard, Claire Le Jeunne, Luc Mouthon, Loïc Guillevin, Benjamin Terrier and for the French Vasculitis Study Group

    Version of Record online : 25 AUG 2016, DOI: 10.1002/art.39663

  15. Combining anti-IgE with oral immunotherapy

    Pediatric Allergy and Immunology

    Chunrong Lin, Ivan T. Lee, Vanitha Sampath, Chitra Dinakar, Rosemarie H. DeKruyff, Lynda C. Schneider and Kari Christine Nadeau

    Version of Record online : 7 SEP 2017, DOI: 10.1111/pai.12767

  16. Lung function parameters in omalizumab responder patients: An interesting tool?


    F. Paganin, G. Mangiapan, A. Proust, A. Prudhomme, J. Attia, S. Marchand-Adam, F. Pellet, F. Milhe, B. Melloni, A. Bernady, C. Raspaud, C. Nocent, P. Berger and L. Guilleminault

    Version of Record online : 14 JUN 2017, DOI: 10.1111/all.13202

  17. You have free access to this content
    Role of immunmodulators in allergen-specific immunotherapy


    Volume 66, Issue 6, June 2011, Pages: 792–797, M. V. Kopp

    Version of Record online : 18 FEB 2011, DOI: 10.1111/j.1398-9995.2011.02553.x

  18. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR


    Volume 59, Issue 7, July 2004, Pages: 709–717, A. M. Vignola, M. Humbert, J. Bousquet, L-P. Boulet, S. Hedgecock, M. Blogg, H. Fox and K. Surrey

    Version of Record online : 4 JUN 2004, DOI: 10.1111/j.1398-9995.2004.00550.x

  19. Individually dosed omalizumab: an effective treatment for severe peanut allergy

    Clinical & Experimental Allergy

    Volume 47, Issue 4, April 2017, Pages: 540–550, J. Brandström, M. Vetander, G. Lilja, S. G. O. Johansson, A.-C. Sundqvist, F. Kalm, C. Nilsson and A. Nopp

    Version of Record online : 10 JAN 2017, DOI: 10.1111/cea.12862

  20. Omalizumab is more effective than suplatast tosilate in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis

    Clinical & Experimental Allergy

    Volume 38, Issue 2, February 2008, Pages: 329–337, T. Nagakura, S. Ogino, K. Okubo, N. Sato, M. Takahashi and T. Ishikawa

    Version of Record online : 7 DEC 2007, DOI: 10.1111/j.1365-2222.2007.02894.x